Role of the Wnt Pathway in Thyroid Cancer

Aberrant activation of Wnt signaling is involved in the development of several epithelial tumors. Wnt signaling includes two major types of pathways: (i) the canonical or Wnt/β-catenin pathway; and (ii) the non-canonical pathways, which do not involve β-catenin stabilization. Among these pathways, the Wnt/β-catenin pathway has received most attention during the past years for its critical role in cancer. A number of publications emphasize the role of the Wnt/β-catenin pathway in thyroid cancer. This pathway plays a crucial role in development and epithelial renewal, and components such as β-catenin and Axin are often mutated in thyroid cancer. Although it is accepted that altered Wnt signaling is a late event in thyroid cell transformation that affects anaplastic thyroid tumors, recent data suggest that it is also altered in papillary thyroid carcinoma (PTC) with RET/PTC mutations. Therefore, the purpose of this review is to summarize the main relevant data of Wnt signaling in thyroid cancer, with special emphasis on the Wnt/β-catenin pathway.

[1]  Reigh-Yi Lin.  Thyroid cancer stem cells , 2011, Nature Reviews Endocrinology.

[2]  D. Rimm,et al.  Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. , 2001, The American journal of pathology.

[3]  D. Medina,et al.  Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. , 2000, European journal of endocrinology.

[4]  T. Sano,et al.  Cribriform‐morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the β‐catenin gene , 2003, The Journal of pathology.

[5]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[6]  A. Johns,et al.  The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. , 2012, Human pathology.

[7]  J. Bernal,et al.  Thyroid Development and Effect on the Nervous System , 2005, Reviews in Endocrine and Metabolic Disorders.

[8]  G. Brabant,et al.  E-cadherin: a differentiation marker in thyroid malignancies. , 1993, Cancer research.

[9]  A. Avallone,et al.  Beta‐ and gamma‐catenin expression in thyroid carcinomas , 1998, The Journal of pathology.

[10]  H. Namba,et al.  Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[12]  J. Herman,et al.  Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. , 1998, Cancer research.

[13]  P. Polakis,et al.  Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. , 1996, Science.

[14]  G. Chiappetta,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society The ret/ptc1 Oncogene Is Activated in Familial , 2022 .

[15]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[16]  G. Piazza,et al.  Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. , 2003, Molecular cancer therapeutics.

[17]  H. Namba,et al.  Aberrant Localization of β-Catenin Correlates with Overexpression of Its Target Gene in Human Papillary Thyroid Cancer , 2002 .

[18]  J. Dick.  Looking ahead in cancer stem cell research , 2009, Nature Biotechnology.

[19]  P. Santisteban,et al.  Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. , 2008, Molecular endocrinology.

[20]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[21]  D. Rimm,et al.  Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. , 1999, Cancer research.

[22]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[23]  N. Dumaz,et al.  Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.

[24]  Marina N. Nikiforova,et al.  Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.

[25]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[26]  Li-xiang Lin,et al.  Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway , 2010, Molecular Biology Reports.

[27]  A. Fusco,et al.  CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas. , 2012, Endocrinology.

[28]  Y. Minami,et al.  Cell/tissue-tropic Functions of Wnt5a Signaling in Normal and Cancer Cells , 2022 .

[29]  G. Brabant,et al.  Wnt/β-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer , 2006 .

[30]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[31]  M. Zannini,et al.  An essential role for Pax8 in the transcriptional regulation of cadherin-16 in thyroid cells. , 2012, Molecular endocrinology.

[32]  G. Brabant,et al.  Identification of a Wnt/β-Catenin Signaling Pathway in Human Thyroid Cells. , 2001, Endocrinology.

[33]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[34]  H. Koeffler,et al.  Molecular Biology of Thyroid Cancer , 2012 .

[35]  Hideki Yamamoto,et al.  Tumor formation due to abnormalities in the β‐catenin‐independent pathway of Wnt signaling , 2008, Cancer Science.

[36]  G. Brabant,et al.  Wnt-5a has tumor suppressor activity in thyroid carcinoma , 2005, Oncogene.

[37]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[38]  A. Fusco,et al.  Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. , 2001, Endocrine reviews.

[39]  D. Rimm,et al.  β-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis , 2001 .

[40]  P. Santisteban,et al.  The BRAF V600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer , 2009 .

[41]  H. Okamoto,et al.  Roles of planar cell polarity pathway genes for neural migration and differentiation , 2009, Development, growth & differentiation.

[42]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[43]  P. Polakis.  The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.

[44]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[45]  G. Berx,et al.  Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.

[46]  M. Todaro,et al.  Tumorigenic and metastatic activity of human thyroid cancer stem cells. , 2010, Cancer research.

[47]  Z. Cohen,et al.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. , 1999, The American journal of pathology.

[48]  S. Friedman,et al.  Thyroid stem cells: lessons from normal development and thyroid cancer. , 2008, Endocrine-related cancer.

[49]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[50]  J. Parma,et al.  The thyrotropin receptor and the regulation of thyrocyte function and growth. , 1992, Endocrine reviews.

[51]  W. Birchmeier,et al.  E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton , 1994, The Journal of cell biology.

[52]  M. Derwahl.  Linking stem cells to thyroid cancer. , 2011, The Journal of clinical endocrinology and metabolism.

[53]  G. Keller,et al.  Directed differentiation of mouse embryonic stem cells into thyroid follicular cells. , 2006, Endocrinology.

[54]  K. Kreuzer,et al.  Physiological inhibitors of Wnt signaling , 2011, European journal of haematology.

[55]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[56]  K. Nephew,et al.  A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer , 2007, Cancer Gene Therapy.

[57]  P DESAIVE,et al.  [Thyroid cancer]. , 1951, Revue medicale de Liege.

[58]  N. Lemoine,et al.  Activating point mutations of the gsp oncogene in human thyroid adenomas , 1991, Molecular carcinogenesis.

[59]  T. Kurihara,et al.  Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. , 2004, Thyroid : official journal of the American Thyroid Association.

[60]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[61]  A. Villa,et al.  Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line. , 2011, American journal of cancer research.

[62]  P. Santisteban,et al.  Molecular biology of thyroid cancer initiation , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[63]  Masahiro Ito,et al.  Correlation of cytoplasmic beta-catenin and cyclin D1 overexpression during thyroid carcinogenesis around Semipalatinsk nuclear test site. , 2003, Thyroid : official journal of the American Thyroid Association.

[64]  R. Moon,et al.  Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. , 2007, The Journal of endocrinology.

[65]  S. Olschwang,et al.  Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. , 2000, The Journal of clinical endocrinology and metabolism.

[66]  C. Vagianos,et al.  Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms , 2008, Modern Pathology.

[67]  M. Willingham,et al.  Regulation of (cid:2) -Catenin by a Novel Nongenomic Action of Thyroid Hormone (cid:2) Receptor (cid:1) , 2022 .

[68]  M. Willingham,et al.  Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma , 2012, Oncogene.

[69]  M. Santoro,et al.  The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. , 2009, Cancer research.

[70]  M. Borrello,et al.  RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. , 2009, Neoplasia.

[71]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[72]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[73]  M. Fraga,et al.  Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer , 2006, Oncogene.

[74]  M. de Felice,et al.  Thyroid development and its disorders: genetics and molecular mechanisms. , 2004, Endocrine reviews.

[75]  N. Patwardhan,et al.  β-Catenin expression in thyroid follicular lesions: Potential role in nuclear envelope changes in papillary carcinomas , 2004, Endocrine pathology.

[76]  A. Carothers,et al.  Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. , 2010, Thyroid : official journal of the American Thyroid Association.